Skip to main content
Fig. 2 | Infectious Diseases of Poverty

Fig. 2

From: Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Fig. 2

Estimates of risk ratio of reactions stratified by any, local, and systematic reactions. Figure shows the risk ratio of any, local, and systemic events in participants who received heterologous ChAd/BNT schedule compared with those in homologous ChAd/ChAd (A) and the risk ratio of any, local, and systemic events in participants who received heterologous ChAd/BNT schedule compared with those in homologous BNT/BNT (B). BNT BNT162b2 vaccine, Pfizer–BioNTech, ChAd ChAdOx1 nCoV-19 vaccine, AstraZeneca, CI confidence intervals, RR risk ratio

Back to article page

Infectious Diseases of Poverty

ISSN: 2049-9957

Contact us